Which manufacturer produces Vebreltinib?

Vebreltinib is an innovative targeted anti-cancer drug independently developed in China. It is developed and produced by a leading domestic biopharmaceutical company. This company has extensive R&D experience in the field of precision tumor treatment and focuses on the development of targeted drugs targeting specific gene mutations or fusion events. Its R&D philosophy emphasizes controlling cancer development by precisely inhibiting key tumor signaling pathways, thereby providing patients with more effective treatments with controllable side effects.

,

The core of the research and development of bripretinib is theMET signaling pathway, which is abnormally activated in a variety of solid tumors, especially in patients with non-small cell lung cancer (NSCLC) and brain glioma. Abnormal MET signaling can lead to abnormal proliferation, migration and invasion of tumor cells, and is closely related to the development of drug resistance. Bripretinib selectively inhibits the activity of MET receptor tyrosine kinase, effectively blocks tumor growth signals, achieves precise anti-tumor effects, and provides a new option for clinical targeted therapy.

Manufacturers strictly follow internationalGMP standards and conduct full-process control of drug raw materials, production processes, quality testing and packaging processes to ensure drug purity, dosage accuracy and long-term stability. Bripretinib is provided in the form of enteric-coated capsules, each containing 100 mg of active ingredients. The enteric-coated design helps the drug to be released stably in the gastric acid environment, improve absorption efficiency, while reducing the risk of gastrointestinal adverse reactions, and improving patient compliance and comfort.

In addition to drug production, the company has also established a complete clinical and medication support system to provide patients with genetic testing services, personalized dosage guidance and long-term follow-up recommendations. By comprehensively assessing the patient's tumor type, gene mutation status, and physical condition, clinicians can formulate the most appropriate precision treatment plan. This full-process support not only ensures drug efficacy, but also provides professional guarantees in safety monitoring, medication education and adverse reaction management.

Reference materials:https://www.asymbio.com.cn/